Should all patients with systemic lupus erythematosus receive cardioprotection with statins?

Nature Clinical Practice Rheumatology

Volumn 3, Issue 10, 2007, Pages 536-537

  Toloza, Sergio ^a   Urowitz, Murray B ^a   Gladman, Dafna D ^a  

^a TORONTO WESTERN HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; GLUCOCORTICOID; HYDROXYCHLOROQUINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO;

ARTERY INTIMA PROLIFERATION; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; HEART PROTECTION; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; LIVER TOXICITY; MUSCLE DISEASE; PRACTICE GUIDELINE; PRIMARY PREVENTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK REDUCTION; SECONDARY PREVENTION; SYSTEMIC LUPUS ERYTHEMATOSUS;

ATHEROSCLEROSIS; CHOLESTEROL, LDL; CORONARY DISEASE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LUPUS ERYTHEMATOSUS, SYSTEMIC; RISK FACTORS;

EID: 34848842786     PISSN: 17458382     EISSN: 17458390     Source Type: Journal    
DOI: 10.1038/ncprheum0593     Document Type: Article

References (11)

1. Nikpour M et al. (2005) Premature atherosclerosis in systemic lupus erythematosus. Rheum Dis Clin North Am 31: 329-354
2. Urowitz MB et al. (1976) The bimodal mortality pattern of systemic lupus erythematosus. Am J Med 60: 221-225
3. Manzi S et al. (1997) Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol 145 408-415
4. Petri M et al. (1992) Coronary artery disease risk factors in the Johns Hopkins Lupus Cohort: Prevalence, recognition by patients, and preventive practices. Medicine (Baltimore) 71: 291-302
5. Ward MM (1999) Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus. Arthritis Rheum 42: 338-346
6. Esdaile JM et al. (2001) Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 44: 2331-2337
7. Bruce IN et al. (1999) Natural history of hypercholesterolemia in systemic lupus erythematosus. J Rheumatol 26: 2137-2143
8. McPherson R et al. (2006) Canadian Cardiovascular Society position statement - recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease. Can J Cardiol 22: 913-927
9. Petri M et al. (2006) Lupus Atherosclerosis Prevention Study (LAPS): A randomized double blind placebo controlled trial of atorvastatin versus placebo. Arthritis Rheum 54 (Suppl): S5-S20
10. Fortin P et al. (2006) The Health Improvement and Prevention Program (HIPP) in systemic lupus erythematosus (SLE) shows preliminary benefits in reducing the estimated 8-year risk of cardiovascular disease.Arthritis Rheum 54 (Suppl): S791
11. Chung CP et al. (2007) High prevalence of the metabolic syndrome in patients with systemic lupus erythematosus: Association with disease characteristics and cardiovascular risk factors. Ann Rheum Dis 66:208-214